Basal cell carcinoma is the most common skin cancer, and it almost never spreads to other parts of the body. It doesn’t stay still either, so for most people the question that matters is how far it digs into the skin around it, not when it will reach an organ. In practice that means treatment within weeks to a few months: no emergency panic, but no leaving it for years.
How Often Basal Cell Carcinoma Spreads to Other Organs
Basal cell carcinoma makes up about 80% of skin cancers that aren’t melanoma.1PubMed Central. Metastatic Basal Cell Carcinoma: A Rare Manifestation of a Common Disease Even so, it reaches other organs in only about 3 in 100,000 to about 1 in 200 cases.2PubMed Central. Metastatic Basal Cell Carcinoma: A Rare Manifestation of a Common Disease Deaths are rare; the main problems are damage near the tumour and the tumour returning.3PubMed Central. Update on the Management of Basal Cell Carcinoma
When spread does happen, it usually follows years of neglect. In one reported case, a facial tumour left untreated about 15 years reached the lungs.4PubMed Central. Pulmonary Metastases From a Long-Standing Untreated Facial Basal Cell Carcinoma: A Rare Case Report That tumour was about 13 by 15 cm, on the head, had invaded bone, and was an aggressive type.5PubMed Central. Pulmonary Metastases From a Long-Standing Untreated Facial Basal Cell Carcinoma: A Rare Case Report The lungs are the most common site when spread occurs, followed by bone and lymph nodes.6Australian Journal of Otolaryngology. Metastatic basal cell carcinoma: a review of six cases Cancer cells can travel there through lymph vessels and the bloodstream.7PubMed. Basal cell carcinoma with pulmonary and lymph node metastasis causing death
There is no fixed timeline. The rare tumours that spread tend to be large, deep and ignored for years, so size, depth and type matter more than time alone.
Melanoma and squamous cell carcinoma both spread more often than basal cell. Basal cell’s danger is mostly local, and that shapes how urgently doctors book treatment.
Doctors don’t scan everyone with basal cell carcinoma, because spread is so rare that routine imaging would find almost nothing. Imaging or lymph node checks come into play when a tumour is very large, has been present for many years, or is an aggressive type. Swollen lumps near the tumour, or new unexplained symptoms such as a persistent cough or bone pain in someone with a long-neglected tumour, are reasons to ask for this assessment.
How Fast It Grows on the Skin
On average, the tumour’s longest width grows about 0.7 mm a month.8PubMed Central. Growth rate of basal cell carcinoma: a meta-analysis and systematic review A spot might therefore widen by roughly 8 to 9 mm over a year. The speed differs by type of tumour, though, and the average is across many tumours, so an individual spot can grow faster or slower. Some seem to sit still for a long time and then enlarge, so a quiet spell doesn’t prove a spot has stopped. You can’t judge the pace by eye, which is why a biopsy and your doctor’s judgement count for more than your own estimate.9PubMed Central. Growth rate of basal cell carcinoma: a meta-analysis and systematic review
Slow growth is easy to miss at home. Common signs are a pearly bump, a sore that bleeds and won’t heal, or a scaly patch. Bleeding, crusting or widening over months can signal growth. Photographing the spot with a ruler beside it helps you and your doctor see change. Slow doesn’t mean harmless: larger tumours need bigger surgery and leave bigger scars.
Depth is usually shallow when the tumour is found. At removal, the typical tumour reaches about 0.68 mm below the surface.10PubMed Central. Depth of Invasion of Aggressive and Nonaggressive Basal Cell Carcinoma Aggressive types typically reach about 1 mm, compared with about 0.6 mm for milder ones, and some reach as deep as 5.5 mm.11PubMed Central. Depth of Invasion of Aggressive and Nonaggressive Basal Cell Carcinoma A tumour that looks small on the surface can therefore be deeper underneath.
Surgeons usually remove a small rim of normal-looking skin around the visible tumour because the cancer can extend slightly beyond what can be seen. Depth is judged under the microscope after removal, so you usually learn how deep it went only from the pathology report. A flat, shiny or scar-like patch can hide more tumour beneath it than a raised bump of the same width.
Which Types Grow and Spread Faster
Your biopsy report will list a subtype, the pattern the cancer cells grow in. That pattern predicts depth: micronodular tumours tend to go deepest, then infiltrative, nodular and superficial.12PubMed. Basal cell carcinoma characteristics as predictors of depth of invasion It predicts depth better than age or other features.13PubMed. Basal cell carcinoma characteristics as predictors of depth of invasion Superficial types do the opposite of digging: they spread widest across the skin while staying shallow.14Dermatology Reports. Growth rate of different basal cell carcinoma subtypes Morpheaform, infiltrative and superficial types show the most actively dividing cells.15PubMed. Cellular proliferation characteristics of basal cell carcinoma: relationship to clinical subtype and histopathology
On the report, look for words such as superficial, nodular, infiltrative, micronodular, morpheaform or basosquamous. Superficial and nodular are usually called low-risk. The others are called high-risk and often get more thorough surgery. Your doctor can tell you which group your type falls in.
Superficial tumours often appear as a flat, pink or red scaly patch that can be mistaken for eczema or a rash that never clears. Nodular tumours are the classic pearly, dome-shaped bump, often with tiny visible blood vessels across the surface. Morpheaform tumours can look like a pale, firm, scar-like patch with poorly defined edges, so they are easy to underestimate.
Infiltrative, micronodular and morpheaform types send out thin strands or small clusters of cells beyond the visible tumour. A surgeon can’t tell where the cancer ends by looking, so these types get more careful margin checking.
Basosquamous carcinoma is the exception. It mixes basal cell and squamous cell features, and it grows faster and comes back more often than ordinary basal cell carcinoma.16PubMed Central. Basosquamous Carcinoma: A Commentary It spreads to other organs in about 4% to 8% of cases.17PubMed Central. Basosquamous Carcinoma: A Commentary Its cells divide about twice as actively as those of typical basal cell cancer.18International Journal of Cancer and Clinical Research. Basosquamous Carcinoma: Report of Two Cases and Review of Literature
Where It Is and Who You Are Can Raise the Risk
The central face, eyes, nose, ears, jaw, lips, hands and feet are higher-risk sites.19PubMed Central. Basal Cell Carcinoma and its Impact on Different Anatomical Regions More than half of basal cell carcinomas appear there, and tumours there are more likely to return, whatever their size.20PubMed Central. Basal Cell Carcinoma and its Impact on Different Anatomical Regions Tumours along the face’s natural joining lines can dig deeper.21PubMed Central. Dermoscopic Pattern of Basal Cell Carcinoma in H- and Non-H-zones
Your report may mention perineural invasion, meaning cancer growing along a nerve.22PubMed Central. Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives It is seen most in aggressive types and deeper tumours, not in superficial ones.23PubMed Central. Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives In one surgical series it turned up in about 7 of 100 tumours, and those tumours needed about 5 rounds of Mohs surgery to clear, versus about 2.24Cancer. Perineural spread of basal cell carcinomas treated with Mohs micrographic surgery On the face it usually follows the nerves for feeling or facial movement.25Neurology. Teaching Neuro Images: Perineural spread of basal cell carcinoma along the trigeminal nerve Numbness, tingling or pain near the spot can be a sign, as can twitching or weakness in facial muscles. Report these to your doctor promptly rather than waiting.
Size matters as well. Tumours 2 cm or larger came back in about 9% of cases, versus under 1% for smaller ones.26PubMed. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter About 6.5% of those large tumours spread or caused death, versus none of the small ones.27PubMed. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter Width of 4 cm or more and growth past the fat layer were the strongest warning signs.28PubMed. Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter
Organ transplant recipients on immune-lowering drugs get these cancers more often,29PubMed. Risk of basal cell carcinoma in Swedish organ transplant recipients: a population-based study and their tumours more often grow deep.30PubMed Central. Basal cell carcinomas in organ transplant recipients versus the general population: clinicopathologic study If that’s you, tell your skin doctor about the transplant drugs or other immune-lowering treatment, ask for regular full skin checks, and have new spots looked at quickly.
“High-risk” is a combination, not one feature. Doctors weigh location, size, type, nerve involvement and whether the tumour has returned. A small tumour on the back may be low-risk, while the same size beside the nose can call for a more thorough approach.
What Happens If You Wait
In one series, people waited on average over 5 years before seeing a specialist.31PubMed. Neglected terebrating cutaneous malignancies in the modern era: A retrospective clinicopathologic case series and determinants of extreme diagnostic delay Fear, denial and self-neglect drove most of that delay, more than slow growth did.32PubMed. Neglected terebrating cutaneous malignancies in the modern era: A retrospective clinicopathologic case series and determinants of extreme diagnostic delay In one case, a facial tumour destroyed sinus and nose bone within 10 months.33PubMed Central. Neglected Basal Cell Carcinomas in the 21st Century A long-untreated tumour cost one man his ear and caused vision loss, pain and trouble chewing.34PubMed Central. Pulmonary Metastases From a Long-Standing Untreated Facial Basal Cell Carcinoma: A Rare Case Report
Slow growth and rare spread lead people to underestimate the harm,35PubMed Central. Delayed Presentation of Basal Cell Carcinoma: A Case Report and delay can turn a small removal into complex surgery.36PubMed. Factors Related to the Delay in the Diagnosis of Basal Cell Carcinoma37PubMed Central. Delayed Presentation of Basal Cell Carcinoma: A Case Report So book a check for any spot that bleeds, grows or won’t heal within a few weeks. A biopsy is usually quick, done in the clinic under local anaesthetic, and gives a definite answer.
After diagnosis, a wait of weeks for a routine surgery slot rarely changes the outcome for small, low-risk tumours. Ask for an earlier date if the tumour is on the central face, growing fast or causing numbness. Bringing a friend or family member can make it easier to go and to remember what was said.
Can It Come Back After Treatment
Mohs surgery removes the tumour layer by layer and checks each layer under a microscope during the procedure. For first-time facial tumours, about 4% came back within 10 years after Mohs and 12% after standard surgery.38PubMed. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up For tumours that had already returned once, Mohs clearly did better: about 4% versus 13.5%.39PubMed. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up More than half of returns after first-time treatment appeared after 5 years.40PubMed. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up Mohs spares as much healthy skin as possible, which matters on the face, and lowers the chance that cancer cells are left at the edges, the usual reason a tumour returns.
A return usually shows up as a new bump, a sore, or a scaly or scar-like change at or beside the original scar. Scar tissue can hide a returning tumour for a while, so any change in an old scar is worth showing your doctor. A return doesn’t mean the cancer has spread, it isn’t a failure on your part, and it can usually be treated again, often with Mohs surgery.
Because late returns are common, being cleared at the 5-year mark doesn’t close the matter completely. Your doctor decides how long to keep seeing you based on the tumour’s type, location and your other risk factors. Between visits, your own checks are the main safeguard: look at the scar monthly for new bumps, sores or bleeding. Having one basal cell carcinoma raises your chance of another, so check all your skin, and use sun protection to lower the risk of new tumours.
Treatment If It Has Spread or Grown Deep
Most basal cell carcinomas are driven by faulty genes in a growth signal pathway.41Elsevier / Journal of Dermatological Science. Hedgehog signaling in basal cell carcinoma Pills that block it, vismodegib and sonidegib, are the first choice for advanced cases.42PubMed Central. Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician If those fail or can’t be tolerated, the immunotherapy drug cemiplimab is an option.43PubMed Central. Managing Advanced Basal Cell Carcinoma: A Guide for the Dermatology Clinician It shrank tumours in about 3 in 10 people, and about half had serious side effects.44PubMed. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Drug treatment is usually reserved for tumours that are too large or in places where surgery or radiation would cause serious disfigurement or loss of function. It is also used when the cancer has spread to other organs, which is rare. A specialist team, often including a skin cancer oncologist, usually decides this together.
These pills are taken by mouth daily or on a schedule, and many people can take them at home. Common side effects include muscle cramps, hair loss, taste changes and tiredness, and these lead some people to pause or stop the drug. They can seriously harm an unborn baby, so pregnancy must be avoided during treatment. Useful questions for your team: whether surgery or radiation can still be used first, how side effects will be watched and managed, and how response will be checked with scans or visits.